{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:51:16Z","timestamp":1791406276075,"version":"4.3.3"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["ZF2025148"],"award-info":[{"award-number":["ZF2025148"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2020206458"],"award-info":[{"award-number":["H2020206458"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2023206295"],"award-info":[{"award-number":["H2023206295"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaut.2025.103414","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T11:31:10Z","timestamp":1743679870000},"page":"103414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases"],"prefix":"10.1016","volume":"153","author":[{"given":"Yuanyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaifang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6391-5617","authenticated-orcid":false,"given":"Wenxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103414_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.jaut.2025.103414_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179351","article-title":"Mechanistic pathways and clinical implications of GLP-1 receptor agonists in type 1 diabetes management","volume":"25","author":"Delrue","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103414_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/antiox13010016","article-title":"Anti-inflammation and anti-oxidation: the key to unlocking the cardiovascular potential of SGLT2 inhibitors and GLP1 receptor agonists","volume":"13","author":"Myasoedova","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.jaut.2025.103414_bib4","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"Eclin. Med."},{"key":"10.1016\/j.jaut.2025.103414_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jaut.2025.103414_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103414_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103414_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2025.103414_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/aje\/kwv292","article-title":"Prediction and prevention of autoimmune disease in the 21st century: a review and preview","volume":"183","author":"Rose","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jaut.2025.103414_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.jaut.2025.103414_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103414_bib12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s13311-021-01088-5","article-title":"Therapeutic potential of a novel glucagon-like peptide-1 receptor agonist, NLY01, in experimental autoimmune encephalomyelitis","volume":"18","author":"Gharagozloo","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaut.2025.103414_bib13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s13311-023-01390-4","article-title":"The effects of NLY01, a novel glucagon-like peptide-1 receptor agonist, on cuprizone-induced demyelination and remyelination: challenges and future perspectives","volume":"20","author":"Gharagozloo","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaut.2025.103414_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109647","article-title":"Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway","volume":"115","author":"Sadek","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jaut.2025.103414_bib15","first-page":"9676","article-title":"Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature","volume":"15","author":"Sonego","year":"2023","journal-title":"Dermatol. Rep."},{"key":"10.1016\/j.jaut.2025.103414_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamainternmed.2014.674","article-title":"Liraglutide-induced autoimmune hepatitis","volume":"174","author":"Kern","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jaut.2025.103414_bib17","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1681\/ASN.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2025.103414_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajhg.2020.12.006","article-title":"Multi-trait transcriptome-wide association studies with probabilistic Mendelian randomization","volume":"108","author":"Liu","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jaut.2025.103414_bib19","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1097\/JS9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jaut.2025.103414_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jacc.2022.06.007","article-title":"Interpreting the clinical implications of drug-target mendelian randomization studies","volume":"80","author":"Ference","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jaut.2025.103414_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103414_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jaut.2025.103414_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ije\/dyy258","article-title":"Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption","volume":"48","author":"Bowden","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.jaut.2025.103414_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.jaut.2025.103414_bib25","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaut.2025.103414_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jaut.2025.103414_bib27","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":"Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials","volume":"96","author":"Buse","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jaut.2025.103414_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1452849","article-title":"IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization","volume":"15","author":"Fu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103414_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1186\/s12967-023-04474-z","article-title":"Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study","volume":"21","author":"Cao","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jaut.2025.103414_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00384-024-04744-2","article-title":"Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis","volume":"39","author":"Fan","year":"2024","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.jaut.2025.103414_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13098-024-01448-z","article-title":"Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis","volume":"16","author":"Mao","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.jaut.2025.103414_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2025.103186","article-title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","volume":"19","author":"Sun","year":"2025","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.jaut.2025.103414_bib33","article-title":"The role of glucagon-like peptide-1 agonists in the treatment of multiple sclerosis: a narrative review","volume":"16","author":"Kaye","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jaut.2025.103414_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3727\/096368911X576027","article-title":"Anti-inflammatory properties of exenatide in human pancreatic islets","volume":"21","author":"Cechin","year":"2012","journal-title":"Cell Transplant."},{"key":"10.1016\/j.jaut.2025.103414_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2337\/db07-1214","article-title":"Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway","volume":"57","author":"Ferdaoussi","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2025.103414_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/CS20110496","article-title":"IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential","volume":"122","author":"Zhu","year":"2012","journal-title":"Clin. Sci."},{"key":"10.1016\/j.jaut.2025.103414_bib37","first-page":"788","article-title":"Autoimmune thyroid disease: further developments in our understanding","volume":"15","author":"Weetman","year":"1994","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jaut.2025.103414_bib38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.arcmed.2016.10.007","article-title":"High thyroid-stimulating hormone levels increase proinflammatory and cardiovascular markers in patients with extreme obesity","volume":"47","author":"G\u00f3mez-Zamudio","year":"2016","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.jaut.2025.103414_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygeno.2024.110795","article-title":"HSCs-derived exosomes regulate the levels of inflammatory cytokines in HIBECs through miR-122-5p mediated p38 MAPK signaling pathway","volume":"116","author":"Zhang","year":"2024","journal-title":"Genomics"},{"key":"10.1016\/j.jaut.2025.103414_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2265.2004.02085.x","article-title":"Cellular immune responses in autoimmune thyroid disease","volume":"61","author":"Weetman","year":"2004","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.jaut.2025.103414_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/19322968241291512","article-title":"Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system","volume":"19","author":"Shah","year":"2025","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jaut.2025.103414_bib42","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.2147\/COPD.S175145","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients","volume":"13","author":"Huang","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.jaut.2025.103414_bib43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/iub.2031","article-title":"Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"71","author":"Tao","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jaut.2025.103414_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/intimm\/dxae031","article-title":"Lipid metabolism: a central modulator of ROR\u03b3t-mediated Th17 cell differentiation","volume":"36","author":"Kanno","year":"2024","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jaut.2025.103414_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103583","article-title":"Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases","volume":"23","author":"Lin","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103414_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108270","article-title":"Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities","volume":"239","author":"Shao","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2025.103414_bib47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-019-0954-6","article-title":"Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway","volume":"18","author":"Wu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jaut.2025.103414_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ph17070828","article-title":"Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network meta-analysis","volume":"17","author":"Liu","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jaut.2025.103414_bib49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jaut.2025.103414_bib50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jaut.2025.103414_bib51","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/ggi.13799","article-title":"Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: a case report","volume":"19","author":"Fukuda","year":"2019","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.jaut.2025.103414_bib52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.jaut.2025.103414_bib53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jdiacomp.2015.12.027","article-title":"Incidence and prevalence of thyroid dysfunction in type 1 diabetes","volume":"30","author":"Nederstigt","year":"2016","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.jaut.2025.103414_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2025.103414_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/biom14060687","article-title":"Implications of GLP-1 receptor agonist on thyroid function: a literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels","volume":"14","author":"Capuccio","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaut.2025.103414_bib56","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J. Dermatol. Treat."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:23:50Z","timestamp":1762316630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":56,"alternative-id":["S0896841125000599"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103414","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103414"}}